Icon

REXULTI (nda205422)- (0.25MG,0.5MG,1MG,2MG,3MG,4MG)

BREXPIPRAZOLE OTSUKA
0.25MG,0.5MG,1MG,2MG,3MG,4MG
Yes No
2033-Apr-12 2020-Jul-10
None None
None No
REXULTI is an atypical antipsychotic indicated for: • Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults • Treatment of schizophrenia in adults and pediatric patients ages 13 years and older.
11 6 4
Total Other Developers 22
Drugs with Suitability No
0.25MG ** ** Up - -
0.5MG ** ** Up - -
1MG ** ** Up - -
2MG ** ** Up - -
3MG ** ** Up - -
4MG ** ** Up - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ****** ****** *** ****** ****** ******* *********** **** **. *-*** /* ***** *** - **** **, *******, ******* ******, ***** (***) ***
****** ****** ****** *************** ******* ******* *********** **** ** ** & **, ******* ******* ******** **** *******-***** *.*. **. **, ***.: ******, ***.: ******, *********, ** ******, ***** (***) ***
****** ****** **** *** * ****** **** ******* *********** **** *, **. **.: ***, ***, *** & ***, ***** *********** ***, ********* *******, ************, ********* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.